P. Glander

K. Budde, F. Diekmann, P. Glander, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric‐Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis

K. Budde, F. Keller, P. Glander, 2007, Journal of clinical pharmacology.

The Severity of Acute Cellular Rejection Defined by Banff Classification Is Associated With Kidney Allograft Outcomes

K. Budde, D. Schmidt, B. Rudolph, 2014, Transplantation.

Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation

K. Budde, D. Schmidt, B. Rudolph, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

CONVERSION FROM TACROLIMUS TO EVEROLIMUS DOES NOT INFLUENCE THE PHARMACOKINETIC BUT INCREASES PHARMACODYNAMIC RESPONSE OF MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS.

K. Budde, W. Arns, P. Glander, 2006 .

CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS LEADS TO BETTER RENAL FUNCTION AND TO PROFOUND CHANGES IN EVEROLIMUS AND MYCOPHENOLATE METABOLISM

K. Budde, W. Arns, P. Glander, 2006 .

Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes

K. Budde, W. Arns, B. Krämer, 2007, Transplantation.

Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients.

K. Budde, F. Diekmann, P. Glander, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Non‐invasive imaging of living kidney donors: intraindividual comparison of multislice computed tomography angiography with magnetic resonance angiography

M. Taupitz, P. Rogalla, K. Budde, 2012, Clinical transplantation.

Biomarkers of Over‐Immunosuppression

K. Budde, P. Glander, M. Dürr, 2011, Clinical pharmacology and therapeutics.

[Modern immunosuppression following renal transplantation. Standard or tailor made?].

K. Budde, P. Glander, H. Neumayer, 2006, Der Urologe. Ausg. A.

Effects of mycophenolic acid alone and in combination with its metabolite mycophenolic acid glucuronide on rat embryos in vitro

M. Shakibaei, P. Glander, R. Stahlmann, 2013, Archives of Toxicology.

Optimization of Therapy with Mycophenolic Acid After Kidney Transplantation

K. Budde, M. Naik, P. Glander, 2011 .

Pre‐Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation

K. Budde, P. Glander, H. Neumayer, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation.

K. Budde, P. Glander, P. Hambach, 2012, Clinica chimica acta; international journal of clinical chemistry.

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

P. Glander, R. Kunert, V. Pistoia, 2013, mAbs.

Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients

K. Budde, C. Sommerer, W. Arns, 2011, Transplantation.

Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism

L. Essioux, W. Weimar, K. Budde, 2009, Pharmacogenetics and genomics.

Target enzyme activity as a biomarker for immunosuppression.

K. Budde, P. Glander, 2010, Therapeutic drug monitoring.

Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells

K. Budde, P. Glander, H. Neumayer, 2009, Therapeutic drug monitoring.

Bioavailability and costs of once‐daily and twice‐daily tacrolimus formulations in de novo kidney transplantation

K. Budde, B. Rudolph, P. Glander, 2018, Clinical transplantation.

Monitoring of gene expression in tacrolimus‐treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study

T. Giese, K. Budde, C. Sommerer, 2021, British journal of clinical pharmacology.

Why rejections are not biopsy proven: frequency and reasons.

K. Budde, P. Glander, H. Neumayer, 2010, Transplantation proceedings.

Reporting of Rejection after Renal Transplantation in Large Immunosuppressive Trials: Biopsy-Proven, Clinical, Presumed, or Treated Rejection?

K. Budde, P. Glander, H. Neumayer, 2006, Transplantation.

The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.

K. Budde, P. Glander, H. Neumayer, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid

L. Weber, B. Tönshoff, V. Armstrong, 2012, European Journal of Clinical Pharmacology.

Cyclosporin C2hour monitoring after renal transplantation.

T. Slowinski, K. Budde, P. Glander, 2003, International journal of clinical pharmacology and therapeutics.

Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans

K. Budde, P. Glander, H. Neumayer, 2007, Therapeutic drug monitoring.

Population Pharmacokinetics of Mycophenolic Acid

M. Pescovitz, K. Budde, P. Glander, 2008, Clinical pharmacokinetics.

Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation

K. Budde, O. Rissling, P. Glander, 2016, Scandinavian journal of clinical and laboratory investigation.

Immune response to an adjuvanted inﬂuenza A H1N1 vaccine (Pandemrix (cid:3) ) in renal transplant recipients

K. Budde, F. Diekmann, P. Glander, 2012 .

Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.

K. Budde, F. Diekmann, P. Glander, 2004, Transplantation proceedings.

Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation.

K. Budde, P. Glander, H. Neumayer, 2006, Transplantation proceedings.

Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients

A. Sattler, K. Budde, T. Dörner, 2022, JCI insight.

Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations

T. Slowinski, K. Budde, P. Glander, 2010, Pharmacogenetics and genomics.

Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A.

T. Slowinski, K. Budde, P. Glander, 2006, Clinical immunology.

Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.

T. Slowinski, K. Budde, P. Glander, 2005, European journal of medical research.

Predictors of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Patients: Baseline Characteristics, Immunosuppression, and the Role of IMPDH Monitoring

K. Budde, D. Schmidt, K. Eckardt, 2022, Journal of clinical medicine.

K. Budde, P. Glander, L. Fritsche, 2007 .

Pharmacokinetic and Pharmacodynamic Comparison of Enteric‐Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients

K. Budde, F. Diekmann, P. Glander, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

The impact of FTY 720 ( fingolimod ) on vasodilatory function and arterial elasticity in renal transplant patients

K. Budde, P. Glander, H. Neumayer, 2007 .

Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells.

K. Budde, I. Roots, P. Glander, 2001, Clinical biochemistry.

Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation.

K. Budde, L. Rostaing, P. Glander, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy.

K. Budde, P. Glander, H. Neumayer, 2002, Transplantation proceedings.

ANALYZING CAUSES FOR DEATH-CENSORED ALLOGRAFT FAILURE IN KIDNEY TRANSPLANT RECIPIENTS

K. Budde, M. Naik, P. Glander, 2020 .

No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.

K. Budde, O. Rissling, P. Glander, 2015, British journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.

K. Budde, C. Sommerer, W. Arns, 2010, Clinical journal of the American Society of Nephrology : CJASN.

A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.

K. Budde, S. Domhan, C. Sommerer, 2013, Clinical nephrology.

Effects of mycophenolic acid alone and in combination with its metabolite mycophenolic acid glucuronide on rat embryos in vitro

M. Shakibaei, P. Glander, R. Stahlmann, 2013, Archives of Toxicology.

Limitations of C2 monitoring in renal transplant recipients.

K. Budde, P. Glander, H. Neumayer, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform.

K. Budde, D. Schmidt, M. Naik, 2021, Journal of visualized experiments : JoVE.

Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients

A. Sattler, M. Oellerich, P. Glander, 2022, medRxiv.

No Evidence for a Relationship Between Infiltrates in Renal Protocol Biopsies and Outcome

T. Slowinski, K. Budde, P. Glander, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISON OF MYCOPHENOLATE MOFETIL (MMF) AND ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN MAINTENANCE RENAL TRANSPLANT PATIENTS WITH TACROLIMUS AS BASIC IMMUNOSUPPRESSION

K. Sandau, K. Budde, P. Glander, 2004 .

SaO014USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY

K. Budde, D. Schmidt, P. Glander, 2018 .

Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.

K. Budde, M. Zeier, P. Glander, 2007, Clinical nephrology.

PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISON OF AN INITIALLY INTENSIFIED DOSING REGIMEN VERSUS A STANDARD DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT PATIENTS.: 717

K. Budde, C. Sommerer, W. Arns, 2008 .

COMPARISON OF AN INITIALLY INTENSIFIED DOSING REGIMEN VERSUS A STANDARD DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT PATIENTS: EFFICACY AND SAFETY ANALYSIS OF 75 PATIENTS.: 266

C. Sommerer, W. Arns, M. Zeier, 2008 .

Pharmacokinetic principles of immunosuppressive drugs.

K. Budde, P. Glander, 2008, Annals of transplantation.

TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients.

K. Budde, D. Schmidt, M. Naik, 2021, Journal of visualized experiments : JoVE.

Pretransplant virtual PRA and long‐term outcomes of kidney transplant recipients

K. Budde, D. Schmidt, M. Naik, 2015, Transplant international : official journal of the European Society for Organ Transplantation.

Problems of cyclosporine absorption profiling using C2-monitoring.

K. Budde, P. Glander, H. Neumayer, 2005, European journal of medical research.

Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation

D. Schmidt, B. Rudolph, P. Glander, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

The 'blood group O problem' in kidney transplantation--time to change?

Klemens Budde, Danilo Schmidt, K. Budde, 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients

P. Glander, N. Lachmann, F. Friedersdorff, 2024, Journal of clinical medicine.